Kybernin P

Antithrombin III, the active ingredient in Kybernin P, is a antithrombin concentrate presented as an injectable solution for intravenous use and marketed in the European Union. It treats congenital antithrombin deficiency and helps prevent thrombosis in deficient patients undergoing surgical procedures, providing a targeted anticoagulant effect under medical supervision.

GNH USA supplies Kybernin P as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide, with a focus on reliable cold‑chain logistics and regulatory compliance and patient safety.

Kybernin P is used in the management of antithrombin deficiency–related coagulation disorders.

- Congenital antithrombin deficiency: restores antithrombin activity to reduce the risk of spontaneous and procedure‑related clot formation. - Surgical patients with antithrombin deficiency: provides prophylactic antithrombin replacement to maintain adequate anticoagulant protection during and after surgery.

Antithrombin concentrate may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Injection site pain or erythema - Mild headache - Transient fever

Serious or Rare Side Effects: - Anaphylactic reaction - Severe bleeding - Disseminated intravascular coagulation

When using Kybernin P, several precautions should be observed to ensure patient safety and product integrity. - Monitor antithrombin activity: measure plasma levels before and after infusion to guide dosing. - Assess bleeding risk: evaluate patient history and concurrent anticoagulant therapy. - Watch for hypersensitivity: discontinue immediately if signs of allergic reaction appear. - Use with caution in renal impairment: adjust monitoring as renal function may affect clearance. - Avoid in uncontrolled active bleeding: the anticoagulant effect may exacerbate hemorrhage. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kybernin P can interact with other medications that affect hemostasis or antithrombin activity.

Major Interactions (Avoid): - Concurrent use with direct oral anticoagulants (e.g., rivaroxaban, apixaban): may cause excessive anticoagulation and bleeding. - Combination with high‑dose heparin: potentiates anticoagulant effect, increasing hemorrhage risk. - Simultaneous administration with other antithrombin concentrates: may lead to supratherapeutic antithrombin levels.

Moderate Interactions (Monitor Closely): - Co‑administration with antiplatelet agents (e.g., aspirin, clopidogrel): monitor for additive bleeding tendency. - Use with non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of gastrointestinal bleeding. - Overlap with fibrinolytic therapy (e.g., alteplase): observe for enhanced clot‑lysis and bleeding.